Blue Wolf Capital is a middle market private equity firm that invests in buyouts, recapitalizations and growth capital opportunities. Since its founding in 2005, to date the firm has raised over $3.1 billion in capital and invested in 32 platforms with 57 follow-on investments in industrial and healthcare companies. Blue Wolf focuses on making control investments and works collaboratively to improve returns through its operational and strategic experience and the integration of environmental, social and governance factors in its investment analysis. Blue Wolf manages challenging situations and complex relationships between business, customers, employees, unions, and regulators with the goal of building value for stakeholders.
Team |
Managing Partner
and Chairman
Managing Partner
Partner
Partner
Promotions Across Firm Reflect Continued Growth and Talent Advancement
NEW YORK, January 14, 2025 – Blue Wolf Capital Partners LLC (“Blue Wolf” or “the firm”), a middle market private equity firm specializing in the healthcare and industrial sectors, today announced new Partner appointments and several other firmwide promotions.
“I am proud to recognize the exceptional contributions of our newly promoted team members, whose impact has been invaluable to Blue Wolf’s mission to build long-term, sustainable businesses and deliver consistent returns for our investors,” said Jeremy Kogler, Managing Partner at Blue Wolf Capital. “These promotions mark another critical milestone in our growth, reaffirming our strong integrated team that continues to drive us forward.”
Partner Appointments
Blue Wolf has named Eve Mongiardo, Shashank Patel, and Rick Winegar as Partners.
Ms. Eve Mongiardo joined Blue Wolf in 2022 as Chief Financial Officer, Chief Compliance Officer, and Managing Director. She oversees all aspects of finance, investor reporting, investment and tax structuring, fundings, valuations, and cash management.
Prior to joining Blue Wolf, Ms. Mongiardo provided consulting and advisory services through her own firm, including CFO advisory services, best practice, operational excellence review, and capital raising initiatives. She spent 12 years with Irving Place Capital, where she was a Partner. Previously, she was the CFO at Soros Private Funds Management and also worked for Goldman Sachs in the Principal Investment Area. She started her career at Deloitte, where she spent four years in the auditing practice. Ms. Mongiardo is a Certified Public Accountant and received a B.S. from Lehigh University and an M.B.A. from New York University’s Stern School of Business.
“It has been remarkable to witness Blue Wolf’s growth over the past several years, driven by our distinctive investment strategy that sets us apart in the market,” said Ms. Mongiardo. “I am honored to be part of this journey as we embrace the exciting opportunities ahead and continue to build on our strong track record.”
Mr. Shashank Patel has served as a Principal at Blue Wolf since 2020, leading the firm’s investments in the healthcare sector, specifically in medical device and pharmaceutical services companies, including CIVCO Radiotherapy and Qfix (now CQ Medical), and a new European-based pharmaceutical manufacturing platform. He previously served in roles with Apax Partners and Providence Equity, as well as Madison Dearborn Partners. Mr. Patel first joined Blue Wolf in 2011 as a Senior Associate focusing on investments in the industrials sector. He began his career in the Mergers and Acquisitions investment banking group at Salomon Smith Barney, now known as Citigroup Global Markets. Mr. Patel received a B.A. and M.S. in Economics and Computer Science from the University of Chicago and an M.B.A. from the Wharton School at the University of Pennsylvania.
“More than a decade after I first joined Blue Wolf, I remain inspired by our ability to partner with exceptional executives, unlock unique value potential, grow our investment platforms, and help our portfolio companies better deliver their products and services to customers and patients worldwide,” said Mr. Patel. “I am as excited to be part of this group today as when I first joined, and it is wonderful to be part of a firm like ours that has scaled while remaining deeply rooted in its core principles.”
Mr. Rick Winegar began collaborating with Blue Wolf in 2011 and formally joined the team in 2012, serving initially as Operating Partner, then Lead Operating Partner, and most recently as Blue Wolf’s COO. He is the architect of the firm’s Operating Partner Program, Portfolio Programs including ESG, and many of Blue Wolf’s foundational playbooks. He currently oversees Blue Wolf internal operations and continues to lead ESG and portfolio programming.
Mr. Winegar has over 30 years of diverse experience across both the healthcare and industrial sectors. Prior to joining the firm, he served in senior roles with Capgemini Consulting and Tunnell Consulting, advising corporate and private equity clients, and in earlier roles led various manufacturing operations at American Cyanamid, a global chemicals producer, and worked as an engineer at Chevon USA. Mr. Winegar received a B.S. in Mechanical Engineering from the University of Missouri-Columbia and an M.B.A. from Columbia University.
“Joining Blue Wolf in 2012 was the beginning of an incredible journey, one that has only become more rewarding over time,” said Mr. Winegar. “The programs and playbooks that we have put in place have become foundational to our ability to find the right investments and build high-performing businesses. I am excited by the strength of our team and look forward to our continued growth and success.”
Additional Promotions
In addition to three new Partner appointments, Blue Wolf has announced several other promotions across various levels at the firm.
The promoted individuals include:
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
Bailey brings vast expertise in sustained growth and operational improvement to the firm’s healthcare portfolio
NEW YORK, December 10, 2024 – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced it is adding Anne Bailey to its roster of operating partners focused on the healthcare industry.
Ms. Bailey brings nearly 30 years of leadership experience across multiple disciplines within healthcare as well as additional industries including aerospace, consumer products, and construction.
She joins Blue Wolf after serving as President of Modivcare Home, a home healthcare business with revenues exceeding $900 million, where she led a nationwide team of over 18,000. Her tenure at Modivcare included leading strategic initiatives that enhanced operational efficiency and profitability and retained a strong focus on patient care and workforce development.
“Anne has a keen understanding of the modern healthcare market and what it takes to run a successful business while also upholding the highest standards of care and employee satisfaction,” said Jeremy Kogler, Managing Partner at Blue Wolf Capital. “Her range of experience in driving growth and ensuring efficient operations will be a large value add to our healthcare portfolio.”
Prior to Modivcare, Anne served as Group Vice President at DaVita, a Fortune 250 healthcare company. There, she oversaw critical business functions, including payer strategy, revenue cycle management, insurance operations, patient engagement, and pharmacy management. As a member of the executive leadership team, she played a pivotal role in shaping the company’s revenue strategies and risk management practices.
“Blue Wolf has a great track record that shows how the right investment partner can transform healthcare companies, to the benefit of both patients and teammates,” said Ms. Bailey. “I’m excited to join Blue Wolf’s experienced operating partners and look forward to working with portfolio company management to support their businesses’ long-term growth and success.”
Ms. Bailey currently serves as a member of the board of directors for OI Infusion, a fast-growing ambulatory infusion business operating in multiple states. She has also served on the boards of several community engagement and advocacy organizations, including the Chronic Disease Coalition, CU Denver Business School, City Year Denver, Amp the Cause, and Access Opportunity.
Ms. Bailey holds a Bachelor’s degree in Economics from the University of California San Diego, a Master’s degree in Information Systems from the University of Colorado, and an MBA with honors from The Wharton School.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
New platform would combine seven European sites acquired from Recipharm with additional facilities in agreed transaction for Synerlab
NEW YORK, September 25, 2024 – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, announced that it has finalized the acquisition of seven European pharmaceutical manufacturing facilities from Recipharm, a leading contract development and manufacturing organization (“CDMO”).
The seven facilities acquired from Recipharm are Solna, Stängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain. With a focus on the production of oral solid, semi-solid, and liquid dosage form pharmaceutical products, these sites serve over 120 customers worldwide and have a strong track record of quality and regulatory compliance.
In addition, Blue Wolf has also agreed, subject to regulatory clearances, to acquire Synerlab, a CDMO headquartered in Strasbourg, France, with six operating facilities in France and Spain. Synerlab has expertise in manufacturing and development across multiple dosage forms, in addition to niche technical processes such as freeze drying and liquid sterile finished dosage forms.
The two transactions mark a significant step forward in helping advance Blue Wolf’s goal of building an industry-leading CDMO.
Blue Wolf also plans to name a new team of experienced pharmaceutical executives who will lead the proposed combined organization and serve on its board of directors. Bruce Vielle, Chief Executive Officer of Synerlab, is expected to serve as Chief Executive Officer of the future platform. He would be joined by:
• Chief Commercial Officer Peter Kruger, previously Chief Business Officer of the facilities Blue Wolf acquired from Recipharm;
• Chief Financial Officer Rich Fenton, previously CFO for the TFL Group and Norgren Europe;
• Chief Operating Officer Steve Leonard, previously Corporate Vice President of Global Operations and Supply Chain at Integra Life Sciences;
• Chief Strategy Officer Saurabh Singh, previously Vice President of Strategy & Business Development for Avet Pharmaceuticals and Director of M&A for AMRI; and
• Group Head of HR, Amy Mort, who previously served in a similar role for the facilities Blue Wolf acquired from Recipharm.
Two long-time CDMO industry executives with deep operational and commercial experience, William Marth and George Svokos, are expected to join the board of directors.
Mr. Marth is President and Chief Operating Officer of Resilience, a technology-focused biomanufacturing company. He was previously the CEO of AMRI (now known as Curia) and spent 14 years at Teva Pharmaceuticals, where he served as President and CEO of Teva Americas.
Mr. Svokos is President and CEO of Avet Pharmaceuticals. He previously served as Chief Operating Officer and Chief Commercial Officer at AMRI and spent more than 30 years in leadership roles at Teva across manufacturing, operations, sales and marketing, and business development.
“I am delighted and enthusiastic to bring the team from the seven Recipharm sites together with Synerlab to build a new CDMO platform,” said Bruce Vielle, Chief Executive Officer of Synerlab. “By honoring both cultures, we will create an even stronger and more exciting one to serve our customers and patients.”
The proposed combined platform, to be headquartered in the UK, would have a manufacturing and employee footprint diversified across major Western European geographies and would serve as the cornerstone of a new best-in-class CDMO. Blue Wolf will support further growth with the goal of expanding the proposed platform’s commercial reach to span across the entire European continent and beyond.
“The opportunity to acquire multi-site, full-service CDMO assets with a track record of delivering high-quality pharmaceutical manufacturing solutions is exciting, and we see significant growth potential in these facilities,” said Shashank Patel, Principal at Blue Wolf. “We look forward to working together with our new partners in Europe to build a best-in-class CDMO focused on delivering outstanding service and exceptional high quality pharmaceutical products to customers and patients worldwide.”
Blue Wolf expects to announce the new corporate name of this platform by the end of the year. Terms of the transaction were not disclosed. The Synerlab transaction is expected to close in Q4 2024, following regulatory approvals.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
Carpenter expands firm’s specialty in the industrials sector
NEW YORK, September 5, 2024 – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced that Mark Carpenter will be joining the firm as an operating partner focused on industrial investments. Most recently, he served as President and Chief Executive Officer of Dayton Superior Corporation (“Dayton Superior”), a leading provider of highly engineered accessories, chemicals, and forming solutions for concrete construction projects.
Mr. Carpenter will join Blue Wolf’s team of experienced operating partners who collaborate closely with the firm’s investment professionals and portfolio company management to provide operational expertise that supports transformation and growth across the portfolio.
“Mark brings operational depth and a track record of accomplishment to his new role as operating partner,” said Jeremy Kogler, Managing Partner at Blue Wolf Capital. “He is an industry veteran who has dedicated his entire career to manufacturing and distribution, and we are eager to welcome him to Blue Wolf.”
“After 25 years in the industrial and manufacturing sectors, I know what makes a strong team and an ideal investment partner, and Blue Wolf embodies both,” said Mr. Carpenter. “I look forward to building on the firm’s deep sector knowledge and track record of success building strong companies.”
Prior to joining Blue Wolf, Mr. Carpenter spent five years at Dayton Superior, where he transformed the company’s supply chain model, significantly grew sales, and developed a new distribution platform focused on engineered solutions and product bundles. Before that, he served as president of Forterra (formerly Hanson Building Products), a senior consultant at Collinson Grant, and a project manager at British American Tobacco.
Mr. Carpenter graduated from Brunel University in London with a B.S. in Engineering and received an M.B.A. from Henley Management College.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
Mike Musuraca announces retirement after more than a decade as Senior Advisor for ESG and Labor
NEW YORK, June 11, 2024 – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced that Steve Sleigh will be a Senior Advisor to the firm. Dr. Sleigh, through his firm Sleigh Strategy LLC, has provided advice to a variety of clients since 2015 on initiatives that align businesses, labor, and investors.
Dr. Sleigh’s new role with Blue Wolf follows the retirement of Mike Musuraca, the firm’s longtime Senior Advisor for ESG and Labor.
“Mike has been a trusted colleague and advisor to Blue Wolf since the firm’s founding almost twenty years ago,” said Adam Blumenthal, Chairman and Managing Partner at Blue Wolf. “His insightful approach to managing complex labor and pension issues has been critical to our growth and success. We are grateful for his many contributions to Blue Wolf and for his friendship to all of us, and we wish him a happy retirement.”
In his new role, Dr. Sleigh will build on the firm’s strong heritage of working with organized labor as a strategy to manage complexity and create value. He will advise the firm on new investments, provide strategic and operational counsel to Blue Wolf’s portfolio companies on labor issues, and help expand Blue Wolf’s partnerships with labor unions and institutional investors.
“Over his career, Steve has earned a reputation as a respected leader with deep experience bringing together labor, business, and investors like Blue Wolf to make transformational investments that build great companies and create good jobs,” said Jeremy Kogler, Managing Partner at Blue Wolf. “Having worked together previously on investment opportunities, we are delighted to welcome Steve and look forward to his contributions to the firm’s continued growth.”
“I’ve known Adam Blumenthal and the Blue Wolf team for over 30 years and have great respect for their distinctive investment approach and track record working with labor,” said Dr. Sleigh. “Blue Wolf is rooted in understanding how businesses, labor, and other stakeholders can work together to achieve growth and great results. I’m excited to be part of this terrific team and to help continue this strong legacy.”
Dr. Sleigh served as Fund Director for the International Association of Machinists and Aerospace Workers’ (“IAM’s”) multi-employer pension, savings, and health plans from 2011 to 2015. Prior to that, he was a principal with the Yucaipa Companies with responsibilities including fundraising, deal sourcing and diligence, and portfolio company governance. Dr. Sleigh also served as Director of Strategic Resources for IAM, Director of Research for the International Brotherhood of Teamsters, and Deputy Director for the Center for Labor Management Policy Studies at the City University of New York.
Dr. Sleigh has also served as co-chair of the Heartland Capital Strategy network for the past ten years and has been a longtime member and past president of the DC Labor and Employment Relations Association and previously served on the boards for Amalgamated Bank (NASDAQ: AMAL) and Americold Logistics (NYSE: COLD). He graduated with a B.A. from University of Massachusetts, Amherst and received a master’s degree in public administration from Harvard University’s Kennedy School of Government and a doctorate in sociology from the City University of New York.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
CHARLOTTE, N.C., June 6, 2024 /PRNewswire/ — Falfurrias Capital Partners (FCP), a private equity firm focused on growth-oriented, middle-market businesses, today announced its investment in EDGE Industrial Technologies (EDGE), a leading producer of industrial machine knives, blades, punches, and related equipment. EDGE’s brands – comprised of TGW International, Pearl Technologies, and Leverwood Knife Works – bring renowned expertise to various global markets, including packaging, food processing, converting, plastics, and printing.
EDGE was formed in 2018 by Blue Wolf Capital Partners LLC (Blue Wolf) to combine TGW International, TGW Global, and Pearl Technologies. In 2021, EDGE acquired Leverwood Knife Works and doubled the company’s previous production capacity. As EDGE undertakes a broadening range of customized industrial blade design projects, it remains committed to maintaining a tradition of excellence and prompt delivery to customers.
FCP’s investment in EDGE will bring new food expertise to the organization. Sauer Brands CEO William Lovette, Pepsico’s former EVP of Engineering and Supply Chain Bill Ladd, and FCP’s Chip Johnson and Ken Walker will join EDGE’s Board along with EDGE’s current CEO, Robert Woodbury. Blue Wolf will also maintain an investment in the company and Board representation, with Aakash Patel continuing to serve. FCP has appointed Josh Slagle to serve as CEO. Josh brings valuable experience to the EDGE team after leading the Nutrition and Health division for SPX Flow.
“I am honored to join the highly talented EDGE team,” said Josh Slagle. “As a driving force in the industry, EDGE has a long history of excellence in quality, technical expertise, and customer service. I am confident that we will build upon that legacy together and significantly expand EDGE’s presence with customers across food processing, packaging, and other served markets. With the combination of EDGE’s strong foundational capabilities and FCP’s added support, the road ahead for the organization is extremely promising.”
“Blue Wolf has been invested in EDGE’s success and has helped the company grow, expand, and deepen its capabilities over the last several years,” said Aakash Patel, EDGE board member and Partner at Blue Wolf. “Falfurrias Capital Partners has a wealth of experience that will be invaluable to the EDGE team, specifically in the food space, where the market continues to surge. With FCP’s partnership and a continued focus on growth and new resources, EDGE is well-positioned for success.”
“EDGE’s commitment to world-class quality, precision, and innovation makes it an optimal platform for growth,” said Ken Walker, Partner at FCP. “We look forward to reinforcing these capabilities and continuing their mission to provide industry-leading cutting solutions to a meaningful and growing customer base.”
About Falfurrias Capital Partners
Falfurrias Capital Partners is a Charlotte-based private equity investment firm founded in 2006 by Hugh McColl Jr., former chairman and CEO of Bank of America; Marc Oken, former CFO of Bank of America; and Managing Partner Ed McMahan. The firm has raised $2.2 billion across six funds and invests in growing, middle market businesses in sectors where the firm’s operational resources, relationships, and sector expertise can be employed to complement portfolio company executive teams in support of growth objectives. Falfurrias Capital Partners employs a proprietary, research-based process called “Industry First” to identify markets with durable growth trends, construct a thesis based on research findings, and partner with management teams and companies to create strategic value. For more information, visit www.falfurrias.com.
About EDGE Industrial Technologies
EDGE Industrial Technologies is comprised of three industry leading brands – TGW International, Pearl Technologies Inc., and Leverwood Knife Works. EDGE companies are leading producers of industrial machine knives and blades, industrial punches, and related equipment, for a variety of markets, including packaging, processing, converting, print, and general industrial applications. EDGE Industrial Technologies is a global leader in the manufacture of these products, with operations in North America, Europe, and Asia.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
NEW YORK, May 8, 2024 – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced that William MacColl has joined the firm as Director of Investor Relations. Prior to joining Blue Wolf, he served as Director of North America Investor Relations for IK Partners, a European private equity platform.
“Having known Will for more than twenty years, I am delighted to welcome him to the Blue Wolf team,” said Jeremy Kogler, Managing Partner at Blue Wolf. “His extensive expertise will help deepen and expand Blue Wolf’s partnerships and help us to communicate the value behind Blue Wolf’s investments.”
“Blue Wolf’s people, their approach towards building high performing companies in industries they know well, and their track record of providing stable, superior returns for investors make this an exciting firm to be part of,” said Mr. MacColl. “I look forward to joining this stellar team to help contribute to the firm’s continued growth.”
Mr. MacColl spent nearly four years as a Director in the Private Capital Advisory business at Lazard, where he focused on raising capital for private equity and other alternative assets. Before Lazard, he was a Vice President at Eaton Partners and has also held positions at Fulcrum Global Partners and Galatioto Sports Partners.
Mr. MacColl graduated from Princeton University with a B.A. in History and received an M.B.A. from Columbia Business School.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
Seven sites across Sweden, France and Spain to form new CDMO platform
April 2, 2024 – NEW YORK – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, announced today that it has committed, subject to regulatory clearances, to acquire seven manufacturing and development facilities: Solna, Stängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain, from Recipharm, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.
The seven facilities have been a part of Recipharm for over a decade and have focused on the manufacturing and development of oral solid, semi-solid and liquid dosage form pharmaceutical products. The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance. Together these sites are to form a new independent CDMO platform with continued focus on pharmaceutical manufacturing operating under a new corporate name to be announced after the transaction closes.
“Blue Wolf is excited for the opportunity to build a new CDMO platform with these seven European assets serving as a cornerstone,” said Shashank Patel, Principal at Blue Wolf. “Partnering with the leadership and teams at these seven facilities, we look forward to continuing to deliver world-class manufacturing capabilities and development services to our partners in order to provide the highest quality pharmaceuticals to patients around the world.”
Greg Behar, CEO, Recipharm said: “We are delighted that Blue Wolf has committed to acquire seven of our OSD sites, marking a significant step for both organizations. I am confident that Blue Wolf will continue to elevate service excellence and bolster the organization for the benefit of customers and patients. By consolidating our site network, we are sharpening our focus on New Chemical Entities (NCEs), medium to high potency drugs, and on-patent medications within the oral solid dosage sector. This strategic divestment aligns with our overarching vision to emerge as the premier choice CDMO for both our customers and patients. I extend my best wishes to all our colleagues embarking on this new journey at those seven sites.”
Terms of the agreement were not disclosed. The transaction is expected to close in Q4 2024, subject to customary regulatory approvals.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, complex union or human capital issues, significant government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing over 7,400 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm and our services, please visit www.recipharm.com
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
Guenaelle Holloway
Head of Communication,
Guenaelle.Holloway@Recipharm.com
New hire marks firm’s second operating partner focused on human capital
NEW YORK, March 26, 2024 – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced that Samantha Dwinell has joined the firm as an operating partner focusing on human capital.
Ms. Dwinell will serve as an advisor for organizational and talent development, supporting Blue Wolf’s investment team on people-centric performance and growth strategies and counseling the firm’s diversified portfolio on areas such as leadership effectiveness, employee experience, and workforce planning.
“Sam is a recognized leader and a champion for high-performing workplaces,” said Jeremy Kogler, managing partner at Blue Wolf Capital. “We place great emphasis at Blue Wolf on fostering and growing talent within our firm and across our portfolio. Sam’s expertise will be a great resource to us, and we are excited she has joined our team.”
Ms. Dwinell is Blue Wolf’s second operating partner specializing in human capital, reinforcing the firm’s strategy of developing strong talent and culture in each of the companies with whom it partners. Prior to joining Blue Wolf, Ms. Dwinell served as Chief People Officer for Stream Realty Partners, a commercial real estate company, and for Sevita, a private equity-backed home and community-based healthcare provider. Before that, she spent nearly 20 years with Texas Instruments.
“Blue Wolf’s strong focus on talent, employee engagement, and development is a hallmark of their investment and growth strategy,” said Ms. Dwinell. “I look forward to working with Blue Wolf and partnering with management teams to ensure our portfolio companies are top destinations for employees.”
Ms. Dwinell graduated from Miami University with a B.A. in Economics and Sociology and received an M.A. from Benedictine University in Management and Organization Behavior as well as an M.H.R.I.R. from the University of Illinois at Urbana-Champaign in Human Resources and Industrial Relations. In 2023, she received OnCon’s Top 50 CHRO Award.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270
New addition broadens firm’s expertise in the healthcare sector
NEW YORK, March 11, 2024 – Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced that David Hecht will be joining the firm as an operating partner specializing in healthcare investments. He most recently served as the chief financial officer and chief strategy officer at RHA Health Services (“RHA”), a leading healthcare services provider to individuals with intellectual and developmental disabilities and those with mental health challenges.
Mr. Hecht joins a roster of respected, seasoned operating partners at Blue Wolf who have deep experience in the healthcare and industrial sectors. In his new role, Mr. Hecht will advise the firm on new healthcare investments and provide strategic and operational counsel to Blue Wolf’s portfolio companies operating in the healthcare sector.
“David was a transformative member of the management team at RHA and will bring strategic thinking and creative problem-solving to his new role,” said Jeremy Kogler, Managing Partner at Blue Wolf Capital. “At Blue Wolf, we remain focused on building our outstanding, integrated team of veteran operating partners and investment professionals. The addition of a proven leader like David reflects our commitment to ensuring we have the operational expertise and sector knowledge necessary to navigate even the most complex issues affecting the industries in which we invest.”
“I am excited to join the talented team at Blue Wolf. Having worked closely with Blue Wolf for nearly five years, I have seen their ability to identify differentiated investments and to create value in their portfolio companies through operational excellence,” said Mr. Hecht. “The healthcare sector presents a wide range of opportunities to invest in businesses that improve health outcomes, deliver a better patient experience, and employ and grow a critical workforce. In pursuit of these goals, I look forward to collaborating with Blue Wolf’s investment team and portfolio company management in my new role.”
Prior to joining Blue Wolf, Mr. Hecht spent seven years at RHA Health Services. During his time there, Mr. Hecht led the company’s finance and capital markets function and helped drive the company’s expansion into multiple new markets, both through acquisition and organic growth. Prior to RHA, Mr. Hecht served as a senior vice president at Formation Capital, a vice president at Healthpro Heritage, and a management consultant at Oliver Wyman, among other roles.
Mr. Hecht graduated from Princeton University with an A.B. in Politics and received an M.B.A. from the Wharton School at the University of Pennsylvania with a concentration in Healthcare Management.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, union or human capital issues, government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.
Contacts
Kate Spaziani
Director, Government Affairs and Communications, Blue Wolf Capital Partners
kate@bluewolfcapital.com
Sam Reinhardt
Vice President, Global Strategy Group
sreinhardt@globalstrategygroup.com
212-392-5270